GV led the genome sequencing company's series B round, which followed a $5.5m series A in late 2014.

Cambridge Epigenetix, a UK-based life sciences spinout from University of Cambridge, yesterday completed a $21m series B round led by GV, the subsidiary of internet group Alphabet formerly known as Google Ventures.

The round also included New Science Ventures, Syncona Partners, Cambridge University and a “significant” investment by Sequoia Capital. Tom Hulme, general partner at GV, will join the company’s board of directors in conjunction with the round.

Cambridge Epigenetix is developing epigenetic sequencing technologies that allow users to discriminate…